



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim
Jeffrey T. Helvey
Eldora L. Ellison
Donald R. Banowit

Peter A. Jackman
Brian J. Del Buono
Mark Fox Evens
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Glenn J. Perry
Theodore A. Wood
Edward W. Yee
Grant E. Reed
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth

Lori A. Gordon
Laura A. Vogel
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
W. Blake Coblentz
James J. Pohl
John T. Haran
Mark W. Rygiel
Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Ulrike Winkler Jenks
Paul A. Calvo
C. Matthew Rozier*
Randall K. Baldwin

Daniel J. Nevriy
Lori M. Brandes
Jeffrey K. Mills*
Mita Mukherjee*
Scott M. Woodhouse*
Christian A. Camarce*
Richard D. Collier III*
Keisha Hylton-Rodic
Bonnie Nannenga-Combs
Alyssa K. Sandrowitz*
Jonathan M. Strang*
Ishan P. Weerakoon*

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Peter A. Socarras
Danielle L. Letting
Steven C. Oppenheimer

Aaron S. Lukas
Gaurav Asthana
Stephanie L. Elmer
Robert E. Bakin
Salvador M. Bezos
Yasser Mourtada

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
Christopher P. Wrist
David C. Isaacson

*Admitted only in Maryland
*Admitted only in Virginia
*Practice limited to
Federal Agencies

August 11, 2008

WRITER'S DIRECT NUMBER:
UNANSWERED
INTERNET ADDRESS:
CDERENZO@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1656

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/553,685; § 371 Date: November 1, 2006
(U.S. National Phase of PCT/US2004/008323)
For: **Nogo Receptor Binding Protein**
Inventors: Mi *et al.*
Our Ref: 2159.0440003/EJH/CLD

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. Form PTO/SB/08A (5 sheets) listing 111 documents (US22-US97 and FP24-FP69);
3. Form PTO/SB/08B (7 sheets) listing 63 documents (NPL33-NPL95);
4. Copies of cited 106 documents (FP24-FP69 and NPL33-NPL92); and
5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.


In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
August 11, 2008
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, reading "Cynthia L. DeRenzo". The signature is written in a cursive, flowing style.

Cynthia L. DeRenzo
Agent for Applicants
Registration No. 60,789

CLD:trh
Enclosures
859152_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mi *et al.*

Appl. No.: 10/553,685 (*U.S. National
Phase of PCT/US2004/008323*)

§371 Date: November 1, 2006

For: **Nogo Receptor Binding Protein**

Confirmation No.: 4041

Art Unit: 1656

Examiner: CARLSON, Karen C.

Atty. Docket: 2159.0440003/EJH/CLD

**First Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on October 19, 2006 in connection with the above-captioned application.

Copies of documents **FP24** to **FP69** and **NPL33** to **NPL92** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US22** to **US97**, cited on the attached IDS Form PTO/SB/08A are not submitted. In addition, copies of documents **NPL93** to **NPL95** are not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited

pending U.S. patent application (or portion of the application which caused it to be listed) is *sua sponte* waived where the cited pending application is stored in the USPTO's IFW system."

The Examiner's attention is directed to the following co-pending U.S. Patent Applications, which are directed to related technical subject matter:

Application No. 11/892,036, inventors Mi *et al.*, continuation of PCT/US2006/026271, international filing date July 7, 2006; and listed as document **NPL93** (NOT PUBLISHED);

Application No. 12/092,662, inventors Mi *et al.*, National Phase of PCT/US2006/042990, international filing date November 3, 2006; and listed as document **NPL94** (NOT PUBLISHED); and

Application No. 12/095,857, inventors Mi *et al.*, National Phase of PCT/US2006/045993, international filing date December 1, 2006; and listed as document **NPL95** (NOT PUBLISHED).

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is

not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed within before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Cynthia L. DeRenzo, Ph.D.
Agent for Applicants
Registration No. 60,789

Date: 8/11/08

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
847249v1